Insmed says Japan health ministry approves BRINSUPRI for non-cystic fibrosis bronchiectasis
INSM•Japan approves BRINSUPRI for expanded use
Japan’s MHLW cleared Insmed’s BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis in adults and children aged 12 and older.
The decision was based on Phase 3 ASPEN data showing fewer pulmonary exacerbations versus placebo over 52 weeks.
Adds to existing U.S. and Europe authorizations
The approval expands BRINSUPRI’s footprint to Japan, adding to existing authorizations in the U.S. and Europe.
